KIORA PHARMACEUTICALS reported that Baselake Partners, Baselake Management and David Paolella each hold or may share voting and dispositive power over 257,500 common shares, representing 5.8% of the outstanding stock. The passive designation matters to investors because the group certified it was not seeking to influence Kiora’s control.

Key Highlights

  • Baselake Partners, Baselake Management and David Paolella each report a 5.8% position in KIORA PHARMACEUTICALS.
  • KIORA’s reported security is common stock with a $0.01 par value.
  • The three reporting parties signed their joint filing statement on September 17, 2026.

KIORA PHARMACEUTICALS INC. (NASDAQ: KPRX) is a Pharmaceuticals: Major company. Baselake Partners, LP, Baselake Management, LLC and David Paolella report shared voting and dispositive power over 257,500 Kiora common shares, a position identified as passive.

Baselake Group Reports 257,500 Shares

The reported position is tied directly to Baselake Partners, which is described as the fund. Baselake Management serves as the fund’s Investment manager, while David Paolella serves as its managing member. The three parties each list 257,500 shares and a 5.8% interest, based on 4,424,387 Kiora shares issued and outstanding as of August 5, 2026. The securities are KIORA PHARMACEUTICALS common stock with a $0.01 par value. The position was reported as of September 10, 2026. The certification also excludes participation in a transaction intended to produce that result, apart from activities solely connected with a nomination under Section 240.14a-11. The report says the three parties may be deemed to share voting and dispositive power because of their relationships. Each disclaims beneficial ownership except to the extent of its pecuniary interest. Baselake Partners, Baselake Management and Paolella signed the joint filing statement on September 17, 2026.